Arrivent Biopharma - 1792 Exchange

Rating Overview

Arrivent Biopharma is Medium Risk.

Arrivent Biopharma, Inc. is Medium Risk. The company often yields to political activism in shaping corporate governance, potentially alienating consumers, dividing employees, and harming shareholders. The company implements race and identity-based policies that replace merit, excellence, and integrity with preferential treatment and outcomes. The company occasionally embraces corporate initiatives that redirect its central focus from business goals to partisan policies and divisive issues at times. This approach fails to safeguard free exercise, free speech, and free enterprise.

Rating Criteria

Corporate Weaponization Risk Levels
Criteria	Risk Level
Cancellations	Medium Risk
Discriminatory Philanthropy	No Data
Employment Protection	High Risk

Corporate Weaponization ⓘ

Corporate Governance and Public Policy Risk Levels
Criteria	Risk Level
Advocacy Bias	Medium Risk
Funding	Lower Risk
Political Actions	No Data

Corporate Governance and Public Policy ⓘ

Rating Criteria Detail

Criteria Risk Level Rationale

Corporate Weaponization

Criteria:

Has canceled customers, suppliers, or vendors due to their political views or religious beliefs OR corporately boycotts, divests, or sanctions regions, people groups, or industries.

Risk Level:

Medium

Rationale:

Arrivent integrates ESG into its business practices. From its Nominating and Corporate Governance Committee Charter: “Oversee the Corporation’s ESG strategy, initiatives and policies, which will include receiving periodic reports from management regarding the Corporation’s ESG efforts and periodically providing reports to the Board on ESG matters” (1). However, the company has not canceled customers, suppliers, or vendors based on political views or religious beliefs (2).

Criteria:

Charitable giving (including employee matching programs) policies or practices discriminate against charitable organizations based on views or religious beliefs.

Risk Level:

N/A

Rationale:

Arrivent does not publish charitable giving guidelines (1).

Criteria:

Employment policies fail to protect against viewpoint or other discrimination and/or are ideological in nature.

Risk Level:

High

Rationale:

Arrivent appears to prioritize diversity over merit in its leadership composition. From its Nomination and Corporate Governance Committee Charter: “The Committee will consider issues of diversity among its members in identifying and considering nominees for director, and will strive where appropriate to achieve a diverse balance of backgrounds, perspectives, experience, age, gender, race, ethnicity, national origin, country of citizenship and other metrics on the Board and its committees” (1). The company does not provide viewpoint protections for its employees (2).

Corporate Governance and Public Policy

Criteria:

Uses corporate reputation to support causes, organizations, or policies hostile to freedom of expression.

Risk Level:

Medium

Rationale:

Arrivent supports ESG within its business practices. From its Nominating and Corporate Governance Committe Charter: “The Nominating and Corporate Governance Committee (the ‘Committee’) is appointed by the Board of Directors (the ‘Board’) of ArriVent BioPharma, Inc… to provide oversight of the Corporation’s environmental, social and governance (‘ESG’) policies and initiatives, including to develop and recommend to the Board corporate governance guidelines applicable to the Corporation” (1). Otherwise, the company has not supported ideological causes or policies (2).

Criteria:

Uses corporate funds to advance ideological causes, organizations, or policies hostile to freedom of expression.

Risk Level:

Lower

Rationale:

Arrivent has not used corporate funds to advance ideological causes, organizations, or policies (1).

Criteria:

Uses corporate political actions and/or financial contributions for ideological, non-business purposes.

Risk Level:

N/A

Rationale:

Arrivent does not operate a PAC or engage in lobbying at this time (1)(2)(3).